In Q3 FY2026 (ended December 27, 2025), Haemonetics reported revenue of $339.0M, down 2.7% year-over-year. Net income rose 19.3% to $44.7M, and operating income increased 14.2% to $67.4M. Diluted EPS grew 28.4% to $0.95.
•Revenue decreased 2.7% YoY to $339.0M.
•Net income increased 19.3% to $44.7M.
•Operating income rose 14.2% to $67.4M.
•Diluted EPS grew 28.4% to $0.95.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Haemonetics Corporation, a medical technology company provides a suite of hospital technologies solutions. Its operations are structured into Plasma, Blood Center, and Hospital segments.
It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions
Integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery.
Its portfolio also includes SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures, and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio
Fiber optic sensor solutions used in medical devices and critical industrial applications. Additionally, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis
TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries.
Its portfolio also includes vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen, and transfusion management solutions. It sells its products through direct sales force and independent distributors. Founded in 1971, the company is headquartered in Boston, Massachusetts.
Haemonetics Corporation is a medical technology company that provides a suite of hospital technology solutions. Its operations are structured into three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection systems like the NexSys PCS plasmapheresis equipment and related disposables, as well as donor management software such as NexLynk DMS and Donor360 tools. In the hospital segment, it provides products for electrophysiology, critical care, trauma, burn surgery, spine surgery, and cancer surgery. Notable products include the SavvyWire sensor-guided guidewire for TAVR procedures, the OptoWire pressure guidewire, the TEG 6s viscoelastic analyzer for hemostasis assessment, and the Cell Saver Elite+ autologous blood recovery system. The company also offers fiber optic sensor solutions for medical devices and industrial applications.
Where is Haemonetics Corporation (HAE) listed and in which currency?
Haemonetics Corporation is listed on the New York Stock Exchange (NYSE) under the ticker symbol HAE. Its financial reporting and trading are conducted in US Dollars (USD). The company is headquartered in the United States, and its shares are traded in the US market.
What sector and industry does Haemonetics Corporation (HAE) operate in?
Haemonetics Corporation operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical technology company, it focuses on developing and providing products and solutions for blood management, plasma collection, and hospital-based diagnostic and therapeutic procedures. Its devices and software support a range of medical fields including cardiology, critical care, surgery, and blood banking.
What are the main products and technologies offered by Haemonetics Corporation (HAE)?
Haemonetics offers a diverse portfolio of products and technologies. In plasma collection, it provides the NexSys PCS plasmapheresis system and related disposables, along with integrated IT platforms for donor management and supply chain. For hospitals, key products include the TEG 6s system, a cartridge-based viscoelastic analyzer that assesses hemostasis, and the TEG Manager software for remote access to test results. The Cell Saver Elite+ is an autologous blood recovery system used in various surgeries. In cardiology, the SavvyWire is a sensor-guided 3-in-1 guidewire for TAVR procedures, and the OptoWire measures fractional flow reserve and diastolic pressure ratio. The company also supplies fiber optic sensor solutions for medical devices and industrial applications.
Which markets and geographies does Haemonetics Corporation (HAE) serve?
Haemonetics Corporation is based in the United States and serves global markets. Its products are used in plasma centers, blood banks, and hospitals worldwide. The company's solutions support a range of medical specialties including electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, cancer surgery, cardiovascular, orthopedic, transplant, vascular, obstetrical, and gynecological surgeries. While the provided data does not specify exact countries, its presence in the US market and international reach is implied by its operations and product portfolio.